Home › Crohn's Disease › Missouri
Crohn's Disease clinical trials in Missouri
21 studies for Crohn's Disease are looking for participants at sites in Missouri.
Cities in Missouri
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- SSM Health Medical Group, Bridgeton
- GI Associates Research, LLC, Columbia
- Mid America Gastro Intestinal Consultants, Kansas City
- and 1 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Mid-America GI Clinical Research ( Site 5130), Kansas City
- BVL Research - Kansas ( Site 5099), Liberty
- Washington University School of Medicine ( Site 5058), St Louis
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 29, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Specialists In Gastroenterology /ID# 283939, St Louis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07697456A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research, Liberty
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06233461Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- GI Associates Research, LLC /ID# 267433, Columbia
- Bvl Research /ID# 265870, Liberty
- Washington University /ID# 266938, St Louis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Washington University School of Medicine, St Louis
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research-Site Number: 8400005, Liberty
- Washington University School of Medicine-Site Number: 8400075, St Louis
- Gateway Gastroenterology-Site Number: 8400097, St Louis
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research-Site Number: 8400005, Liberty
- Gateway Gastroenterology-Site Number: 8400097, St Louis
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- University Health Truman Medical Center, Kansas City
- and 6 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- KAD Clinical Research, St Louis
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483073A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- KAD Clinical Research, St Louis
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483099A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Washington University School of Medicine, St Louis
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- SSM Health DePaul Hospital- St. Louis, Bridgeton
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 22, 2026 · NCT06226883A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Mid-America Gastro-Intestinal Consultants, Kansas City
- BVL Clinical Research, Liberty
- Washington University School of Medicine, St Louis
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- BVL Research - Kansas ( Site 0292), Liberty
RecruitingPhase 3
All ages · All sexes · Updated Sep 9, 2026 · NCT06651281DB-3Q for the Treatment of Medically Refractory Crohn's Disease
- Washington University, St. Louis, St Louis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 1, 2026 · NCT07625293Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
- Washington University School of Medicine, St Louis
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jun 5, 2026 · NCT06976853A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400013, St Louis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Mar 27, 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bridgeton
- Mirador Therapeutics Selected Site, Kansas City
- Mirador Therapeutics Selected Site, Liberty
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Washington University in St. Louis, St Louis
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Dec 10, 2025 · NCT06721962Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Washington University in St Louis School of Medicine, St Louis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2025 · NCT06670638From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.